10X1000-TECH
Fintech training platform 10x1000 Tech for Inclusion (“10x1000”) today released its results for 2021. With the vision to train 1,000 emerging talents and tech leaders each year for ten years, the platform saw a total of 1,067 learners from 66 countries and regions complete its Fintech Foundation Program and Fintech Leadership Program in 2021, and receive certifications from 10x1000 and the International Finance Corporation (IFC). Close to 80% of its learners are from South and Southeast Asia, with Bangladesh, Indonesia and the Philippines ranking as the top three countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220331006106/en/
Mr. Jason Pau, Program Lead of 10x1000 said: “Deepening understanding of emerging technology applications, cross-region sharing and local networking are the top three priorities for learners embarking on 10x1000 programs. Realizing the potential for cross-country and cross-region knowledge sharing, 10x1000 has also focused on connecting and fostering a vibrant global fintech community of learners, experts and partners to cultivate learning. In 2021, 17 expert lecturers and 31 leading global organizations, tech investors, and industry organizations have joined the community as our close partners to collectively identify learners for 10x1000.”
“I encourage everyone in the financial ecosystem—including banks, fintechs, and regulators—to continue exploring development and market opportunities given the current fast-paced digitization and technological changes. Doing so will promote a balanced development that focuses on financial inclusion, consumer protection, cybersecurity, and digital financial literacy,” said Hans Koning, Global Chief Digital Finance Strategist at IFC. “Innovative programs like 10X1000 Tech for Inclusion are important to empower future digitization and tech leaders further increase their knowledge and skills to become drivers of sustainable innovation in emerging markets.”
On the back of a strong year, 10x1000 also announced a series of new and enhanced learning programs for 2022:
1. Fintech Expert Program
- The Fintech Expert Program will be introduced to further the learning journey for tech professionals.
- Through eight recorded video lectures, the program is designed to bring learners through a deep-dive into various topics ranging from AI, Blockchain to Cloud to gain practical knowledge and skillsets.
2. Green Fintech Miniseries
- To enhance awareness on ESG and green fintech, the miniseries will feature three recorded video lectures on real-life case studies and best practices.
3. Fintech Foundation Program in French
- To better meet the demand and reach more learners globally, 10x1000 will make its Fintech Foundation Program available in French.
Mr. Pau added: “We are committed to expand curriculums to provide a continuous and widely accessible learning journey for fintech and tech professionals worldwide. We sincerely welcome more experts and partners to join hands in our collective goal of bridging the digital skills gap and driving financial inclusion.”
Training content provided by 10x1000 is being guided by a Curriculum Steering Committee (CSC), an advisory body responsible for ensuring the quality and effectiveness of the curriculum. The current committee is composed of global experts from industry, academia, and international financial institutions.
About 10x1000 Tech for Inclusion
10x1000 Tech for Inclusion is an open and global fintech training platform that enables learners to become drivers of digital economic growth. Its mission is to train 1,000 emerging talents and tech leaders each year for the next ten years. 10x1000 is a philanthropic initiative launched jointly by the International Finance Corporation (IFC), a member of the World Bank Group, and Alipay in 2018.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331006106/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom